<DOC>
	<DOC>NCT01452373</DOC>
	<brief_summary>The purpose of this Phase III trial is to evaluate the efficacy of oral administration of dehydroepiandrosterone (DHEA) combined with acolbifene (a selective estrogen receptor modulator (SERM)) on vasomotor symptoms (hot flushes) in postmenopausal women.</brief_summary>
	<brief_title>Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Flushing</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<mesh_term>Selective Estrogen Receptor Modulators</mesh_term>
	<criteria>Main Postmenopausal women (nonhysterectomized or hysterectomized). Women between 40 and 75 years of age. Willing to participate in the study and sign an informed consent. Women having many moderate to severe hot flushes. For nonhysterectomized women, willing to have an endometrial biopsy at baseline and end ofstudy. Main Undiagnosed abnormal genital bleeding. Hypertension equal to or above 140/90 mm Hg. The administration of any investigational drug within 30 days of screening visit. Endometrial hyperplasia (simple or complex hyperplasia with or without atypia), cancer or endometrial histology showing proliferative, secretory or menstrual type characteristics at histologic evaluation of endometrial biopsy performed at screening.</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Hot flush(es)</keyword>
	<keyword>Hot flash(es)</keyword>
	<keyword>Vasomotor symptoms</keyword>
	<keyword>Dehydroepiandrosterone (DHEA)</keyword>
	<keyword>Prasterone</keyword>
	<keyword>Acolbifene</keyword>
	<keyword>Selective estrogen receptor modulator (SERM)</keyword>
	<keyword>Antiestrogen</keyword>
	<keyword>Menopause</keyword>
	<keyword>Postmenopausal women</keyword>
</DOC>